Trial · NCT00326183
Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED)
NCT00326183, Phase 4, Completed, Merck Sharp & Dohme LLC; results first posted 2008-11-20
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED). Trials, record NCT00326183. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00326183
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED)
- NCT number
- NCT00326183
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 1,800 participants, actual
- Lead sponsor
- Merck Sharp & Dohme LLC
- Conditions
- Hepatitis A, Measles, Mumps, Rubella, Chickenpox
- Interventions
- VAQTA®, ProQuad
- First posted
- 2006-05-16
- Last updated
- 2019-02-04
- Results first posted
- 2008-11-20
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Participants With 1 or More Serious Vaccine-Related Adverse Experiences | Days 1 to 14 after any vaccination | |
| Primary | Participants With 1 or More Injection-Site Adverse Experiences | Days 1 to 14 after any vaccination | |
| Primary | Participants With Measles-Like Rash After First Vaccination | Days 1 to 28 After First Vaccination | |
| Primary | Participants With Measles-Like Rash After Second Vaccination | Days 1 to 28 After Second Vaccination | |
| Primary | Participants With Mumps-Like Symptoms After First Vaccination | Days 1 to 28 After First Vaccination | |
| Primary | Participants With Mumps-Like Symptoms After Second Vaccination | Days 1 to 28 After Second Vaccination | |
| Primary | Participants With Rubella-Like Rash After First Vaccination | Days 1 to 28 After First Vaccination | |
| Primary | Participants With Rubella-Like Rash After Second Vaccination | Days 1 to 28 After Second Vaccination | |
| Primary | Participants With Varicella/Zoster-Like Rash After First Vaccination | Days 1 to 28 After First Vaccination | |
| Primary | Participants With Varicella/Zoster-Like Rash After Second Vaccination | Days 1 to 28 After Second Vaccination |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes12
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Participants With 1 or More Serious Vaccine-Related Adverse Experiences | Days 1 to 14 after any vaccination | Includes all subjects who provided safety follow-up data after any dose of vaccine out of the total number of subjects enrolled. | participants | NUMBER |
| SECONDARY | Participants With 1 or More Systemic Adverse Experiences | Days 1 to 14 After Any Vaccination | Includes all subjects who provided safety follow-up data after any dose of vaccine out of the total number of subjects enrolled. | participants | NUMBER |
| PRIMARY | Participants With 1 or More Injection-Site Adverse Experiences | Days 1 to 14 after any vaccination | Includes all subjects who provided safety follow-up data after any dose of vaccine out of the total number of subjects enrolled. | participants | NUMBER |
| PRIMARY | Participants With Measles-Like Rash After First Vaccination | Days 1 to 28 After First Vaccination | Includes all subjects who provided safety follow-up data after the first vaccinations were administered. Only the VAQTA™ +ProQuad™ group was followed for rashes. | participants | NUMBER |
| PRIMARY | Participants With Measles-Like Rash After Second Vaccination | Days 1 to 28 After Second Vaccination | Includes all subjects who provided safety follow-up data after the second vaccinations were administered. Only the VAQTA™ + ProQuad™ group was followed for rashes. | participants | NUMBER |
| PRIMARY | Participants With Mumps-Like Symptoms After First Vaccination | Days 1 to 28 After First Vaccination | Includes all subjects who provided safety follow-up data after the first vaccinations were administered. Only the VAQTA™ + ProQuad™ group was followed for mumps-like symptoms. | participants | NUMBER |
| PRIMARY | Participants With Mumps-Like Symptoms After Second Vaccination | Days 1 to 28 After Second Vaccination | Includes all subjects who provided safety follow-up data after the second vaccinations were administered. Only the VAQTA™ + ProQuad™ group was followed for mumps-like symptoms. | participants | NUMBER |
| PRIMARY | Participants With Rubella-Like Rash After First Vaccination | Days 1 to 28 After First Vaccination | Includes all subjects who provided safety follow-up data after the first vaccinations were administered. Only the VAQTA™ + ProQuad™ group was followed for rashes. | participants | NUMBER |
| PRIMARY | Participants With Rubella-Like Rash After Second Vaccination | Days 1 to 28 After Second Vaccination | Includes all subjects who provided safety follow-up data after the second vaccinations were administered. Only the VAQTA™ + ProQuad™ group was followed for rashes. | participants | NUMBER |
| PRIMARY | Participants With Varicella/Zoster-Like Rash After First Vaccination | Days 1 to 28 After First Vaccination | Includes all subjects who provided safety follow-up data after the first vaccinations were administered. Only the VAQTA™ + ProQuad™ group was followed for rashes. | participants | NUMBER |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 outcomesResults by group16
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Participants With 1 or More Serious Vaccine-Related Adverse Experiences | Arm 1: VAQTA™ | 0 | participants | ||
| Participants With 1 or More Serious Vaccine-Related Adverse Experiences | Arm 2: VAQTA™ +ProQuad™ | 1 | participants | ||
| Participants With 1 or More Systemic Adverse Experiences | Arm 1: VAQTA™ | 782 | participants | ||
| Participants With 1 or More Systemic Adverse Experiences | Arm 2: VAQTA™ +ProQuad™ | 197 | participants | ||
| Participants With 1 or More Injection-Site Adverse Experiences | Arm 1: VAQTA™ | 701 | participants | ||
| Participants With 1 or More Injection-Site Adverse Experiences | Arm 2: VAQTA™ +ProQuad™ | 164 | participants | ||
| Participants With Measles-Like Rash After First Vaccination | Arm 2: VAQTA™ +ProQuad™ | 13 | participants | ||
| Participants With Measles-Like Rash After Second Vaccination | Arm 2: VAQTA™ +ProQuad™ | 5 | participants | ||
| Participants With Mumps-Like Symptoms After First Vaccination | Arm 2: VAQTA™ +ProQuad™ | 0 | participants | ||
| Participants With Mumps-Like Symptoms After Second Vaccination | Arm 2: VAQTA™ +ProQuad™ | 0 | participants |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 results by groupParticipant flow14
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Arm 1: VAQTA™ | 1,453 | |
| Overall Study | STARTED | Arm 2: VAQTA™ +ProQuad™ | 347 | |
| Overall Study | Vaccination 1 + Safety Follow-up | Arm 1: VAQTA™ | 1,453 | |
| Overall Study | Vaccination 1 + Safety Follow-up | Arm 2: VAQTA™ +ProQuad™ | 347 | |
| Overall Study | Postvaccination 1 Post-safety Follow-up | Arm 1: VAQTA™ | 1,393 | |
| Overall Study | Postvaccination 1 Post-safety Follow-up | Arm 2: VAQTA™ +ProQuad™ | 325 | |
| Overall Study | Vaccination 2 + Safety Follow-up | Arm 1: VAQTA™ | 1,301 | |
| Overall Study | Vaccination 2 + Safety Follow-up | Arm 2: VAQTA™ +ProQuad™ | 292 | |
| Overall Study | Postvaccination 2 Post-safety Follow-up | Arm 1: VAQTA™ | 1,265 | |
| Overall Study | Postvaccination 2 Post-safety Follow-up | Arm 2: VAQTA™ +ProQuad™ | 271 |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 participant flowAdverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 30431383 | BACKGROUND |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons4
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Arm 1: VAQTA™ vs Arm 2: VAQTA™ +ProQuad™: Participants With Elevated Temperature (>=102.2F/39.0C) | Trial comparisons |
| Arm 1: VAQTA™ vs Arm 2: VAQTA™ +ProQuad™: Participants With 1 or More Injection-Site Adverse Experiences | Trial comparisons |
| Arm 1: VAQTA™ vs Arm 2: VAQTA™ +ProQuad™: Participants With 1 or More Serious Vaccine-Related Adverse Experiences | Trial comparisons |
| Arm 1: VAQTA™ vs Arm 2: VAQTA™ +ProQuad™: Participants With 1 or More Systemic Adverse Experiences | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00326183
GET https://conductscience.org/api/trials/v1/NCT00326183/registered